Clinical Trials on Healthy Individuals in Japan

Total 360 results

Eisai Co., Ltd.

Completed

E2022 Patch Formulation Single Dose Phase I Study

Japanese Healthy Male Adult Volunteers

Japan
Astellas Pharma Inc

Completed

A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet (Without Water) and Conventional Tablet

Healthy | Plasma Concentration of YM060

Japan
Astellas Pharma Inc

Completed

A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150 Tablet

Healthy Volunteer | Pharmacokinetics of YM150

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

A Phase I Study of TS-172 in Healthy Adult Subjects (Single and Multiple Doses)

Healthy Adult Subjects

Japan
EA Pharma Co., Ltd.

Completed

A Single Intravenous Dose of E3112 in Japanese Healthy Adult Male Participants

Healthy Male Participants

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Evaluation Study of the Bioavailability of Brexpiprazole Orally Disintegrating Tablets in Healthy Male Subjects

Healthy Adult Male

Japan
EA Pharma Co., Ltd.

Completed

A Single Intravenous Dose Study of E3112 in Japanese Healthy Adult Male Subjects

Healthy Male Volunteers

Japan
Nestlé

Completed

Feasibility Clinical Study of NLA Tool

Healthy Elder People

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study of OPC-41061 Orally Disintegrating (OD) Tablets Using 2 Different Formulations and 2 Dosing Regimens in Healthy Adult Male Subjects

Healthy Adult Male

Japan
Eisai Co., Ltd.

Completed

A Phase 1 Single Dose Study of E6011 in Japanese Healthy Adult Male Subjects (Study E6011-J081-001)

Healthy Male Volunteers

Japan
Boehringer Ingelheim

Completed

A Study in Healthy Japanese Men to Test How Different Doses of BI 1323495 Are Tolerated and How Itraconazole Influences the Amount of BI 1323495 in the Blood

Healthy

Japan
Pfizer

Completed

Investigation of Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single-Dose of PF-06823859 in Japanese Healthy Participants

Healthy

Japan
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0003)

Healthy

Japan
Telavant, Inc.
Pfizer

Completed

Evaluation of Safety, Tolerability and Pharmacokinetics of Single Dose of PF-06480605 in Japanese Healthy Participants

Healthy

Japan
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Completed

A Study About How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated in Healthy Japanese Men

Healthy

Japan
Boehringer Ingelheim

Completed

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 764198 Are Tolerated

Healthy

Japan
Eli Lilly and Company

Completed

A Study of LY3537031 in Healthy Participants

Healthy

Japan
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Bioequivalence Study For Orally-Disintegrating Tablet Of Sildenafil

Healthy

Japan
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Bioequivalence Of Zoloft ODT To Jzoloft In Healthy Japanese Subjects

Healthy

Japan
Boehringer Ingelheim

Completed

A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2

Healthy

Japan
Pfizer

Completed

Evaluation of Skin Irritation Potential With PF-06700841 Cream Formulation Using Negative Control in Adult Japanese Healthy Participants

Healthy

Japan
Pfizer

Completed

A Single and Multiple Dose Study of PF-05221304 in Healthy Japanese Adults

Healthy

Japan
Boehringer Ingelheim

Completed

Bioavailability Study of Five Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects

Healthy

Japan
Boehringer Ingelheim

Completed

Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects

Healthy

Japan
Pfizer

Completed

Phase 1 Study to Characterize the Safety and Pharmacokinetics of Single Intravenous Dose of Lorazepam in Healthy Japanese Adult Subjects

Healthy

Japan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Pharmacokinetics of HCV-796 in Healthy Japanese Men

Healthy

Japan
Astellas Pharma Inc

Completed

A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet and Conventional Tablet Under With Water Intake

Healthy | Plasma Concentration of YM060

Japan
Takeda

Completed

A Phase 1 Food Effect Study of Azilsartan (TAK-536) Pediatric Formulation

Healthy Volunteers

Japan
Astellas Pharma Inc

Completed

A Study to Investigate the Plasma Concentration of YM150 After Repeated Administration to Elderly Subjects

Healthy Elderly Subject | Pharmacokinetic of YM150

Japan
Nobelpharma

Completed

A Study of NPC-22 in Healthy Adult Males

Healthy Adult Subjects

Japan
Astellas Pharma Inc

Completed

Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine

Healthy | Pharmacokinetics of Mirabegron and Tolterodine

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

Safety, Pharmacokinetic, and Pharmacodynamic Study of TS-142 in Healthy Subjects

Healthy Volunteer

Japan
Takeda

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Doses With Titration of TAK-935 in Healthy Japanese Participants

Healthy Volunteer

Japan
Eisai Co., Ltd.

Completed

A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy Participants

Healthy Participants

Japan
Eisai Co., Ltd.

Completed

A Study to Assess the Safety and Tolerability of E6742 in Japanese Healthy Adult Participants

Healthy Volunteers

Japan
Takeda

Completed

Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)

Healthy Volunteers

Japan
Zeria Pharmaceutical

Completed

A Healthy Subject Study With Z-360 and Placebo

Healthy Volunteers

Japan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of HSD-016

Healthy Subjects

Japan
Eisai Co., Ltd.

Terminated

Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2082 in Healthy Male Subjects

Healthy Participants

Japan
Astellas Pharma Inc

Completed

A Study to Assess Effect of Exercise Program Provided by Smartphone Application on the Body Composition

Healthy Volunteers

Japan
Takeda

Completed

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-123 After Intravenous Infusion in Japanese Healthy Adult Male Participants

Healthy Volunteers

Japan
Eisai Co., Ltd.

Completed

Bioequivalence Study Between a 4-mg Dose of Fine Granules of Perampanel and a 4-mg Tablet of Perampanel in Healthy Japanese Subjects

Healthy Participants

Japan
Takeda

Completed

Single-Dose Study of MT203

Healthy Volunteers

Japan
Eisai Co., Ltd.

Completed

A Study of APD356 (Lorcaserin) in Healthy Japanese Adult Subjects

Healthy Subjects

Japan
Eisai Co., Ltd.

Completed

Single/ Multiple-Dose Study of E6007 in Healthy Japanese Male Subjects

Healthy Volunteers

Japan
Eisai Co., Ltd.

Completed

A Bioequivalence Study Comparing Improved Versus Current Orally Disintegrating E2020 10 mg Tablet in Healthy Japanese Adult Males

Healthy Adult

Japan
Eisai Co., Ltd.

Completed

A Bioequivalence Study of Film-coated Tablet and Dry Syrup 1% Form for E2020 in Healthy Japanese Adult Males

Healthy Adult

Japan
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and PK Following Single and Multiple Ascending Doses of AZD7295 in Japanese

Healthy Subjects

Japan
Astellas Pharma Inc

Completed

Study to Evaluate the Effect of Food Intake on the Plasma Concentration Changes of Quetiapine After Oral Administration of FK949E in Healthy Volunteers

Healthy | Plasma Concentration Change of Quetiapine

Japan

3

Subscribe